Table 1 Basal characteristics of enrolled AFL patients (before CTI-ablation treatment; n = 95)
Age (yr) | 64.4 ± 10.6 |
Males, n (%) | 77 (81,1) |
COPD, n (%) | 20 (21,1) |
Hypertension, n (%) | 47 (49,5) |
Diabetes mellitus, n (%) | 19 (20,0) |
Obese, n (%) | 25 (26,3) |
LVEF <50%, n (%) | 22 (23,1) |
Hypertensive cardiopathy, n (%) | 37 (38,9) |
Valvulopathy, n (%) | 19 (20,0) |
Ischaemic heart disease, n (%) | 14 (14,7) |
Heart Failure, n (%) | 18 (18,9) |
Dilated cardiomyopathy, n (%) | 21 (22,1) |
Previous cardiac surgery, n (%) | 12 (12,6) |
No heart disease, n (%) | 20 (21,1) |
Cor Pulmonale, n (%) | 5 (5,3) |
Type of AFL, n (%) | |
Persistent | 53 (55,8) |
Paroxysmal | 42 (44,2) |
Ventricular cycle length, ms | 653 ± 223 |
Paroxysmal | 641 ± 260 |
Persistent | 686 ± 192 |
Duration of AFL, months | 12 [3, 48] |
AFL episodes, n | 2 [1,7] |
Previous ECV, n (%) | 22 (23,2) |
Previous PCV, n (%) | 15 (15,8) |
Previous anticoagulation treatment, n (%) | 55 (57,9) |
1 year follow –up anticoagulation treatment n (%) | 63 (66,3) |
Previous AF, n (%) | 41 (43,2) |
Class I- III drugs related AFL, n (%) | 14 (14,7) |
Flecainide | 3 (3,1) |
Amiodarone | 11 (11,6) |
Tachycardiomyopathy, n (%) | 16 (16,8) |